US20150313868A1 - Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - Google Patents

Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity Download PDF

Info

Publication number
US20150313868A1
US20150313868A1 US14/649,951 US201314649951A US2015313868A1 US 20150313868 A1 US20150313868 A1 US 20150313868A1 US 201314649951 A US201314649951 A US 201314649951A US 2015313868 A1 US2015313868 A1 US 2015313868A1
Authority
US
United States
Prior art keywords
carbamate
disorders
exposure
cbd
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/649,951
Other languages
English (en)
Inventor
Joseph Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOTZKER CONSULTING LLC
Original Assignee
KOTZKER CONSULTING LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOTZKER CONSULTING LLC filed Critical KOTZKER CONSULTING LLC
Priority to US14/649,951 priority Critical patent/US20150313868A1/en
Assigned to KOTZKER CONSULTING LLC reassignment KOTZKER CONSULTING LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MORGAN, JOSEPH
Publication of US20150313868A1 publication Critical patent/US20150313868A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
US14/649,951 2012-12-18 2013-12-18 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity Abandoned US20150313868A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/649,951 US20150313868A1 (en) 2012-12-18 2013-12-18 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738782P 2012-12-18 2012-12-18
PCT/US2013/076223 WO2014100231A1 (fr) 2012-12-18 2013-12-18 Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate
US14/649,951 US20150313868A1 (en) 2012-12-18 2013-12-18 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/076223 A-371-Of-International WO2014100231A1 (fr) 2012-12-18 2013-12-18 Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/004,004 Continuation US11266623B2 (en) 2012-12-18 2018-06-08 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity

Publications (1)

Publication Number Publication Date
US20150313868A1 true US20150313868A1 (en) 2015-11-05

Family

ID=50979163

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/649,951 Abandoned US20150313868A1 (en) 2012-12-18 2013-12-18 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US16/004,004 Active 2034-02-12 US11266623B2 (en) 2012-12-18 2018-06-08 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US16/945,839 Active US11464758B2 (en) 2012-12-18 2020-08-01 Cannabinoid co-drug compounds
US17/589,012 Pending US20220151981A1 (en) 2012-12-18 2022-01-31 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/004,004 Active 2034-02-12 US11266623B2 (en) 2012-12-18 2018-06-08 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US16/945,839 Active US11464758B2 (en) 2012-12-18 2020-08-01 Cannabinoid co-drug compounds
US17/589,012 Pending US20220151981A1 (en) 2012-12-18 2022-01-31 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity

Country Status (5)

Country Link
US (4) US20150313868A1 (fr)
EP (1) EP2934512B1 (fr)
CA (1) CA2895805A1 (fr)
IL (1) IL238946B (fr)
WO (1) WO2014100231A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216538A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry Powder Inhaler
WO2017218845A1 (fr) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Procédés et compositions pour réduire le stress oxydatif
WO2017218846A1 (fr) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Procédés et compositions de potentialisation de thérapies de cellules souches
WO2018057596A1 (fr) * 2016-09-21 2018-03-29 JC Pharma, Inc. Méthode et composition pour le traitement des crises
WO2018118197A1 (fr) * 2016-12-21 2018-06-28 Richard Postrel Vieillissement en meilleure santé pour les animaux domestiques
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
EP3443956A1 (fr) * 2017-08-18 2019-02-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composé augmentant la concentration d'endocannabinoïdes chez un sujet pour une utilisation dans la prévention et/ou le traitement d'un trouble du comportement social
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
JP2019523282A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
JP2019523283A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
WO2019220324A3 (fr) * 2018-05-14 2020-01-02 Buzzelet Development And Technologies Ltd Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses
WO2020006597A1 (fr) * 2018-07-03 2020-01-09 Zelda Therapeutics Operations Pty Ltd Composition cannabinoïde et procédé de traitement de la ptsd et/ou de l'angoisse
WO2020006599A1 (fr) * 2018-07-03 2020-01-09 Zelda Therapeutics Operations Pty Ltd Composition et procédé de traitement de la douleur
US10555928B2 (en) 2014-10-21 2020-02-11 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2020051158A1 (fr) * 2018-09-04 2020-03-12 Gustin John C Compositions ayant un agent et un activateur de celui-ci, procédés d'utilisation et systèmes de distribution
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
WO2021127749A1 (fr) * 2019-12-24 2021-07-01 Cannadol Pharmaceuticals Ltd Compositions comprenant des terpènes et leur utilisation dans le traitement ou le soulagement de la douleur ou de l'anxiété
CN113573710A (zh) * 2019-02-07 2021-10-29 迈迪普尔医药公司 基于大麻素受体激动剂和丝氨酸水解酶抑制剂的抗焦虑治疗产品
US11260033B2 (en) 2018-12-11 2022-03-01 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
US11654111B2 (en) * 2016-02-11 2023-05-23 Satipharm Ag Oral solid cannabinoid formulations, methods for producing and using thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
ES2784229T3 (es) * 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
WO2016187722A1 (fr) * 2015-05-27 2016-12-01 Mary Lynch Utilisation de cannabinoïdes dans le traitement de l'inflammation et/ou de la douleur oculaire
ES2877361T3 (es) 2014-06-27 2021-11-16 Farm To Farma Inc Formulaciones de cannabinoides bucales y sublinguales y método para hacer las mismas
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
MX2021010033A (es) * 2014-12-12 2022-08-25 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides.
CN105802951B (zh) * 2014-12-30 2021-03-05 丰益(上海)生物技术研发中心有限公司 固定化脂肪酶及其制备方法和用途
CA2977802A1 (fr) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprenant des combinaisons de cannabinoides purifies, ayant au moins un flavonoide, terpene ou mineral
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
WO2017007833A1 (fr) * 2015-07-06 2017-01-12 George Marc Compléments sains
IL301006A (en) * 2016-03-16 2023-04-01 Buzzelet Development And Technologies Ltd Cannobinoid compounds are rich in terpenes
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017319320B2 (en) 2016-08-29 2023-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2019089558A1 (fr) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Interfaces utilisateur graphiques permettant de déterminer des génotypes d'endocannabinoïde personnalisés et des recommandations associées
WO2019118205A1 (fr) * 2017-12-12 2019-06-20 Daisy Pharma Opioid Venture, Llc Procédés de renforcement et/ou d'économie d'opioïdes à partir d'associations co-administrées ou à dose fixe de dronabinol et d'un opioïde
WO2019159174A1 (fr) * 2018-02-16 2019-08-22 Icdpharma Ltd. Administration, dans le côlon, de cannabinoïdes dans des compositions de solution solide
WO2020061687A1 (fr) * 2018-09-28 2020-04-02 Visceral Therapeutics Inc. Compositions pharmaceutiquement actives à base de cannabis et procédés d'utilisation pour traiter des affections gastro-intestinales
WO2020097358A1 (fr) * 2018-11-07 2020-05-14 Columbia Care, Llc Formulations de suppositoire ayant un cannabinoïde
GB2615034A (en) 2018-12-18 2023-07-26 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
US11471437B2 (en) 2019-06-18 2022-10-18 Opiant Pharmaceuticals, Inc. Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
EP3986396A4 (fr) * 2019-06-18 2023-08-02 Opiant Pharmaceuticals, Inc. Compositions et méthodes de traitement du surdosage aigu aux cannabinoïdes avec un antagoniste des récepteurs cannabinoïdes
CA3170635A1 (fr) 2020-03-04 2021-09-10 Ginger D. Constantine Procedes et compositions pour traiter un trouble de l'usage du cannabis et attenuer les symptomes du sevrage des cannabinoides
US20210369651A1 (en) * 2020-05-28 2021-12-02 Sollievo Pharmaceuticals, Inc Parenteral delivery of avizafone
MX2023003967A (es) * 2020-10-05 2023-06-15 Max Biology Co Ltd Composiciones que contienen cannabinoides y uso para tratar y prevenir enfermedades.
US20240000809A1 (en) * 2020-11-16 2024-01-04 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023081873A1 (fr) * 2021-11-05 2023-05-11 Quorum Innovations, Llc Matériaux et procédés pour prévenir ou réduire la toxicité d'organophosphates et d'autres matériaux toxiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2478595A (en) * 2010-03-12 2011-09-14 Gw Pharma Ltd Phytocannabinoids for use in the treatment of cancer
US20120059062A1 (en) * 2002-02-01 2012-03-08 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096740A (en) 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6211230B1 (en) 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
AU2002331595A1 (en) 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
CA2551127A1 (fr) * 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Traitement de douleur aigue par inhalation en aerosol de medicaments
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
EP2314289A1 (fr) * 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9035130B2 (en) 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
WO2009059018A1 (fr) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer les réponses immunitaires dirigées contre une bactérie flagellée
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US20110257256A1 (en) 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2513167B (en) 2013-04-18 2016-03-02 Otsuka Pharma Co Ltd Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
WO2014178048A1 (fr) 2013-05-02 2014-11-06 Mor Research Applications Ltd. Cannabidiol destiné à la prévention et au traitement de la maladie du greffon contre l'hôte

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059062A1 (en) * 2002-02-01 2012-03-08 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2478595A (en) * 2010-03-12 2011-09-14 Gw Pharma Ltd Phytocannabinoids for use in the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fischedick et al.; “Cannabinoid Receptor 1 Binding Activity and Quantitative Analysis of Cannabis sativa L. Smoke and Vapor”; 2010; Chem. Pharm. Bull.; 58(2): 201-207 *
Maccarrone et al.; “Estrogen stimulated arachidonoylethanolamide release from human endothelial cells and platelet activation; 2002; Blood; 100: 4040-4048 *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
US10638792B2 (en) 2013-03-15 2020-05-05 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10667560B2 (en) 2013-12-23 2020-06-02 Juul Labs, Inc. Vaporizer apparatus
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
US11752283B2 (en) 2013-12-23 2023-09-12 Juul Labs, Inc. Vaporization device systems and methods
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10058124B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10070669B2 (en) 2013-12-23 2018-09-11 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10264823B2 (en) 2013-12-23 2019-04-23 Juul Labs, Inc. Vaporization device systems and methods
US10117465B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10117466B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10912331B2 (en) 2013-12-23 2021-02-09 Juul Labs, Inc. Vaporization device systems and methods
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10201190B2 (en) 2013-12-23 2019-02-12 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10701975B2 (en) 2013-12-23 2020-07-07 Juul Labs, Inc. Vaporization device systems and methods
US10555928B2 (en) 2014-10-21 2020-02-11 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US11291650B2 (en) 2014-10-21 2022-04-05 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
US20170216538A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry Powder Inhaler
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US11654111B2 (en) * 2016-02-11 2023-05-23 Satipharm Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
WO2017218846A1 (fr) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Procédés et compositions de potentialisation de thérapies de cellules souches
EP3471745A4 (fr) * 2016-06-15 2020-01-22 Ojai Energetics PBC Procédés et compositions pour réduire le stress oxydatif
US20190247358A1 (en) * 2016-06-15 2019-08-15 Ojai Energetics Pbc Methods and compositions for potentiating stem cell therapies
CN109641022A (zh) * 2016-06-15 2019-04-16 奥海能量公益公司 用于减少氧化应激的方法和组合物
WO2017218853A1 (fr) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Procédés et compositions pour réduire le stress oxydatif
WO2017218845A1 (fr) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Procédés et compositions pour réduire le stress oxydatif
USD929036S1 (en) 2016-06-16 2021-08-24 Pax Labs, Inc. Vaporizer cartridge and device assembly
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD913583S1 (en) 2016-06-16 2021-03-16 Pax Labs, Inc. Vaporizer device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US11779562B2 (en) 2016-08-03 2023-10-10 Zelira Therapeutics Operations Pty Ltd Cannabis composition
AU2021240297B2 (en) * 2016-08-03 2023-08-24 Zelira Therapeutics Operations Pty Ltd Cannabis Composition
JP2019523283A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
JP2019523282A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10206901B2 (en) * 2016-09-21 2019-02-19 JC Pharma, Inc. Method and composition for acute treatment of seizures
WO2018057596A1 (fr) * 2016-09-21 2018-03-29 JC Pharma, Inc. Méthode et composition pour le traitement des crises
WO2018118197A1 (fr) * 2016-12-21 2018-06-28 Richard Postrel Vieillissement en meilleure santé pour les animaux domestiques
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
EP3443956A1 (fr) * 2017-08-18 2019-02-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composé augmentant la concentration d'endocannabinoïdes chez un sujet pour une utilisation dans la prévention et/ou le traitement d'un trouble du comportement social
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
USD927061S1 (en) 2017-09-14 2021-08-03 Pax Labs, Inc. Vaporizer cartridge
WO2019220324A3 (fr) * 2018-05-14 2020-01-02 Buzzelet Development And Technologies Ltd Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses
WO2020006597A1 (fr) * 2018-07-03 2020-01-09 Zelda Therapeutics Operations Pty Ltd Composition cannabinoïde et procédé de traitement de la ptsd et/ou de l'angoisse
AU2019297198B2 (en) * 2018-07-03 2022-12-08 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
WO2020006599A1 (fr) * 2018-07-03 2020-01-09 Zelda Therapeutics Operations Pty Ltd Composition et procédé de traitement de la douleur
WO2020051158A1 (fr) * 2018-09-04 2020-03-12 Gustin John C Compositions ayant un agent et un activateur de celui-ci, procédés d'utilisation et systèmes de distribution
US11260033B2 (en) 2018-12-11 2022-03-01 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN113573710A (zh) * 2019-02-07 2021-10-29 迈迪普尔医药公司 基于大麻素受体激动剂和丝氨酸水解酶抑制剂的抗焦虑治疗产品
WO2021127749A1 (fr) * 2019-12-24 2021-07-01 Cannadol Pharmaceuticals Ltd Compositions comprenant des terpènes et leur utilisation dans le traitement ou le soulagement de la douleur ou de l'anxiété

Also Published As

Publication number Publication date
US20200375940A1 (en) 2020-12-03
US20180311205A1 (en) 2018-11-01
US11266623B2 (en) 2022-03-08
EP2934512B1 (fr) 2021-11-24
IL238946B (en) 2019-03-31
IL238946A0 (en) 2015-07-30
EP2934512A4 (fr) 2016-10-19
US20220151981A1 (en) 2022-05-19
US11464758B2 (en) 2022-10-11
WO2014100231A1 (fr) 2014-06-26
CA2895805A1 (fr) 2014-06-26
EP2934512A1 (fr) 2015-10-28

Similar Documents

Publication Publication Date Title
US11464758B2 (en) Cannabinoid co-drug compounds
Golightly et al. Pharmaceutical excipients: adverse effects associated with inactive ingredients in drug products (Part I)
Moshiri et al. Advances in toxicology and medical treatment of chemical warfare nerve agents
US10172870B2 (en) Method of treating organophosphate intoxication by administration of neurosteroids
Taylor Anticholinesterase agents
ES2629185T3 (es) Derivados de morfinano para el tratamiento de la diabetes y trastornos relacionados
TWI745280B (zh) 注毒液治療及相關醫藥組成物、系統及套組
JP2019530751A (ja) 神経変性疾患を処置するためのカンナビノイド含有複合混合物
MX2014006961A (es) Composiciones de dexmedetomidina intranasal y sus metodos de uso.
US20150224094A1 (en) Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20150297601A1 (en) Phosphodiesterase inhibitor treatment
AU2013305569A1 (en) Composition for the treatment of migraine headaches
CA2957224A1 (fr) Procede de traitement de syndrome prader-willi
El-Hashim et al. Anti-tussive and bronchodilator mechanisms of action for the enaminone E121
US20210393615A1 (en) Methods for treating neurological conditions and exposure to nerve agents
US20230125585A1 (en) Dosing protocols and regimens for aminosterol treatment
US20190321426A1 (en) Combination therapies with cannabis plant extract
US20100035998A1 (en) Combination s-nitrosothiol pharmaceutical products for restoring normal breathing rhythms
US20190314297A1 (en) Combination therapy of cbd and copaxone
EP4186509A1 (fr) Alpha-1062 pour le traitement d&#39;une lésion cérébrale traumatique
US20200338090A1 (en) Seizure control compositions and methods of using same
CA3231407A1 (fr) Traitement de troubles neurologiques
CA2500090A1 (fr) Produit pharmaceutique a application endonasale pour traiter des maladies et des troubles du systeme nerveux central
WO2023215277A1 (fr) Triméprazine destiné à être utilisé dans le traitement de la névralgie du trijumeau et pour réduire la douleur associée à celle-ci
EP1749528A1 (fr) Combinaisons pharmaceutiques comprenant un agoniste de l&#39;opioide mu et un inhibiteur de la production de monoxide d&#39;azote

Legal Events

Date Code Title Description
AS Assignment

Owner name: KOTZKER CONSULTING LLC, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MORGAN, JOSEPH;REEL/FRAME:035792/0635

Effective date: 20150604

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION